Vanguard Group Inc Revance Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
A detailed history of Vanguard Group Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 5,994,459 shares of RVNC stock, worth $15.4 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
5,994,459
Previous 5,398,406
11.04%
Holding current value
$15.4 Million
Previous $26.6 Million
42.0%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding RVNC
# of Institutions
202Shares Held
81.8MCall Options Held
490KPut Options Held
147K-
Capital World Investors Los Angeles, CA13.9MShares$35.8 Million0.01% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA6.26MShares$16.1 Million0.01% of portfolio
-
Palo Alto Investors LP Palo Alto, CA5.26MShares$13.5 Million1.71% of portfolio
-
Polar Capital Holdings PLC London, X03.57MShares$9.17 Million0.06% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...